- Home
- MBRX vs HKPD Comparison
MBRX vs HKPD Comparison
Compare MBRX & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBRX
- HKPD
- Stock Information
- Founded
- MBRX 2015
- HKPD 2016
- Country
- MBRX United States
- HKPD Hong Kong
- Employees
- MBRX N/A
- HKPD N/A
- Industry
- MBRX Biotechnology: Pharmaceutical Preparations
- HKPD Other Pharmaceuticals
- Sector
- MBRX Health Care
- HKPD Health Care
- Exchange
- MBRX Nasdaq
- HKPD Nasdaq
- Market Cap
- MBRX 24.3M
- HKPD 20.9M
- IPO Year
- MBRX 2016
- HKPD 2025
- Fundamental
- Price
- MBRX $0.48
- HKPD $1.55
- Analyst Decision
- MBRX Strong Buy
- HKPD
- Analyst Count
- MBRX 4
- HKPD 0
- Target Price
- MBRX $5.00
- HKPD N/A
- AVG Volume (30 Days)
- MBRX 3.0M
- HKPD 1.4M
- Earning Date
- MBRX 11-07-2025
- HKPD 08-14-2025
- Dividend Yield
- MBRX N/A
- HKPD N/A
- EPS Growth
- MBRX N/A
- HKPD N/A
- EPS
- MBRX N/A
- HKPD N/A
- Revenue
- MBRX N/A
- HKPD $20,313,818.00
- Revenue This Year
- MBRX N/A
- HKPD N/A
- Revenue Next Year
- MBRX N/A
- HKPD N/A
- P/E Ratio
- MBRX N/A
- HKPD N/A
- Revenue Growth
- MBRX N/A
- HKPD 21.72
- 52 Week Low
- MBRX $0.25
- HKPD $0.81
- 52 Week High
- MBRX $3.65
- HKPD $3.79
- Technical
- Relative Strength Index (RSI)
- MBRX 55.74
- HKPD 58.88
- Support Level
- MBRX $0.39
- HKPD $1.51
- Resistance Level
- MBRX $0.51
- HKPD $1.82
- Average True Range (ATR)
- MBRX 0.03
- HKPD 0.14
- MACD
- MBRX 0.02
- HKPD 0.02
- Stochastic Oscillator
- MBRX 84.47
- HKPD 54.24
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
About HKPD Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and (ii) OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.